1 January 2024 false No description of principal activity Taxfiler 2024.6 13111010business:PrivateLimitedCompanyLtd2024-01-012024-12-31 131110102023-12-31 131110102024-01-012024-12-31 13111010business:AuditExemptWithAccountantsReport2024-01-012024-12-31 13111010business:FilletedAccounts2024-01-012024-12-31 131110102024-12-31 13111010business:Director12024-01-012024-12-31 13111010business:RegisteredOffice2024-01-012024-12-31 131110102023-12-31 13111010core:WithinOneYear2024-12-31 13111010core:WithinOneYear2023-12-31 13111010core:ShareCapitalcore:PreviouslyStatedAmount2024-12-31 13111010core:ShareCapitalcore:PreviouslyStatedAmount2023-12-31 13111010core:SharePremiumcore:PreviouslyStatedAmount2024-12-31 13111010core:SharePremiumcore:PreviouslyStatedAmount2023-12-31 13111010core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-12-31 13111010core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-12-31 13111010core:PreviouslyStatedAmount2024-12-31 13111010core:PreviouslyStatedAmount2023-12-31 13111010business:SmallEntities2024-01-012024-12-31 13111010countries:EnglandWales2024-01-012024-12-31 13111010core:ComputerEquipment2024-01-012024-12-31 13111010core:IntangibleAssetsOtherThanGoodwill2023-12-31 13111010core:IntangibleAssetsOtherThanGoodwill2024-12-31 13111010core:ComputerEquipment2023-12-31 13111010core:ComputerEquipment2024-12-31 13111010business:OrdinaryShareClass12024-01-012024-12-31 13111010business:OrdinaryShareClass12023-01-012023-12-31 13111010business:OrdinaryShareClass22024-01-012024-12-31 13111010business:OrdinaryShareClass22023-01-012023-12-31 13111010business:OrdinaryShareClass32024-01-012024-12-31 13111010business:OrdinaryShareClass32023-01-012023-12-31 13111010business:OrdinaryShareClass42024-01-012024-12-31 13111010business:OrdinaryShareClass42023-01-012023-12-31 13111010business:OrdinaryShareClass52024-01-012024-12-31 13111010business:OrdinaryShareClass52023-01-012023-12-31 13111010business:AllOrdinaryShares2024-01-012024-12-31 13111010business:AllOrdinaryShares2023-01-012023-12-31 131110102023-01-012023-12-31 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 13111010 (England and Wales)
Enbiosis Biotechnology Limited Unaudited accounts for the year ended 31 December 2024
Enbiosis Biotechnology Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Enbiosis Biotechnology Limited Company Information for the year ended 31 December 2024
Director
Omer Ozkan
Company Number
13111010 (England and Wales)
Registered Office
25 Cabot Square London E14 4QZ United Kingdom
Accountants
Pro Accountants 85 Great Portland Street First Floor London W1W 7LT
- 3 -
Enbiosis Biotechnology Limited Statement of financial position as at 31 December 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Intangible assets
4
468,542 
468,542 
Tangible assets
5
719 
- 
Investments
6
7,345 
7,345 
476,606 
475,887 
Current assets
Debtors
7
945,983 
642,192 
Cash at bank and in hand
2,558 
233,190 
948,541 
875,382 
Creditors: amounts falling due within one year
8
(413,470)
(569,048)
Net current assets
535,071 
306,334 
Net assets
1,011,677 
782,221 
Capital and reserves
Called up share capital
9
137 
131 
Share premium
1,228,608 
842,513 
Profit and loss account
(217,068)
(60,423)
Shareholders' funds
1,011,677 
782,221 
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 11 September 2025 and were signed on its behalf by
Omer Ozkan Director Company Registration No. 13111010
- 4 -
Enbiosis Biotechnology Limited Notes to the Accounts for the year ended 31 December 2024
1
Statutory information
Enbiosis Biotechnology Limited is a private company, limited by shares, registered in England and Wales, registration number 13111010. The registered office is 25 Cabot Square, London, E14 4QZ, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
33.33 on a straight line basis
4
Intangible fixed assets
Other 
£ 
Cost
At 1 January 2024
468,542 
At 31 December 2024
468,542 
Amortisation
At 1 January 2024
- 
At 31 December 2024
- 
Net book value
At 31 December 2024
468,542 
At 31 December 2023
468,542 
- 5 -
Enbiosis Biotechnology Limited Notes to the Accounts for the year ended 31 December 2024
5
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 1 January 2024
- 
Additions
1,048 
At 31 December 2024
1,048 
Depreciation
Charge for the year
329 
At 31 December 2024
329 
Net book value
At 31 December 2024
719 
6
Investments
Subsidiary undertakings 
£ 
Valuation at 1 January 2024
7,345 
Valuation at 31 December 2024
7,345 
7
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
2,988 
3,591 
Trade debtors
33,558 
1,433 
Amounts due from group undertakings etc.
909,437 
637,168 
945,983 
642,192 
8
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Trade creditors
13,306 
4,060 
Taxes and social security
19,526 
1,235 
Other creditors
312,257 
563,133 
Loans from directors
67,831 
220 
Accruals
550 
400 
413,470 
569,048 
- 6 -
Enbiosis Biotechnology Limited Notes to the Accounts for the year ended 31 December 2024
9
Share capital
2024 
2023 
£ 
£ 
Allotted, called up and fully paid:
26,579 Class A GBP of £0.001 each
26.57 
26.57 
73,421 Common GBP of £0.001 each
73.42 
73.42 
4,060 Class A USD of £0.001 each
4.06 
3.41 
32,440 Class B USD of £0.001 each
32.44 
27.56 
710 Common USD of £0.001 each
0.71 
0.31 
137.20 
131.27 
Shares issued during the period:
650 Class A USD of £0.001 each
0.65 
4,880 Class B USD of £0.001 each
4.88 
400 Common USD of £0.001 each
0.40 
5.93 
10
Average number of employees
During the year the average number of employees was 3 (2023: 2).
- 7 -